Non-Current Liabilities

Operating Lease Liabilities (Total)

Regeneron Pharmaceuticals Operating Lease Liabilities (Total) increased by 13.8% to $266.80M in Q4 2025 compared to the prior quarter. Over 2 years (FY 2023 to FY 2025), Operating Lease Liabilities (Total) shows an upward trend with a 74.4% CAGR.

Analysis

StatementBalance Sheet Statement
SectionNon-Current Liabilities
CategoryRisk
SignalContext dependent
VolatilityStable
First reportedQ4 2019
Last reportedQ4 2025

How to read this metric

A significant increase reflects a long-term commitment to physical expansion, while a decrease suggests a consolidation of facilities or a move toward remote operations.

Detailed definition

The total present value of all future lease payments for operating leases, covering both short-term and long-term horizo...

Peer comparison

Used to compare the 'fixed charge' burden across companies with different strategies regarding owning versus leasing real estate.

Metric ID: operating_lease_liabilities_total

Historical Data

3 periods
 Q4 '23Q4 '24Q4 '25
Value$87.70M$234.40M$266.80M
QoQ Change—+167.3%+13.8%
YoY Change—+167.3%+13.8%
Range$87.70M – $266.80M
Avg YoY Growth+90.5%
Median YoY Growth+90.5%
Current Streak2+ quarters growth

Operating Lease Liabilities (Total) at Other Companies

RVM
Revolution Medicines, Inc.RVMDView metric

Frequently Asked Questions

What is Regeneron Pharmaceuticals's operating lease liabilities (total)?
Regeneron Pharmaceuticals (REGN) reported operating lease liabilities (total) of $266.80M in Q4 2025.
What is the long-term trend for Regeneron Pharmaceuticals's operating lease liabilities (total)?
Over 2 years (2023 to 2025), Regeneron Pharmaceuticals's operating lease liabilities (total) has grown at a 74.4% compound annual growth rate (CAGR), from $87.70M to $266.80M.
What does operating lease liabilities (total) mean?
The total amount of money the company is committed to paying for all its rented properties and equipment over time.